Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Dividends

Explore dividend yields, payout ratios, and historical trends to maximize your investment strategies.

Last Close
May 20 10:57AM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-19.22 Insider Own- Shs Outstand2.97M Perf Week28.66%
Market Cap0.30M Forward P/E- EPS next Y- Insider Trans- Shs Float- Perf Month65.70%
Income-8.80M PEG- EPS next Q- Inst Own19.88% Short Float- Perf Quarter-23.08%
Sales0.47M P/S0.64 EPS this Y- Inst Trans-10.06% Short Ratio0.71 Perf Half Y-51.32%
Book/sh0.38 P/B3.27 EPS next Y- ROA-87.62% Short Interest2.06M Perf Year-92.58%
Cash/sh31.71 P/C0.04 EPS next 5Y- ROE-180.18% 52W Range0.67 - 20.39 Perf YTD-53.50%
Dividend Est.- P/FCF- EPS past 5Y86.34% ROI-138.80% 52W High-93.89% Beta1.50
Dividend TTM- Quick Ratio1.26 Sales past 5Y53.21% Gross Margin- 52W Low85.99% ATR (14)0.16
Dividend Ex-Date- Current Ratio1.26 EPS Y/Y TTM99.06% Oper. Margin-2115.65% RSI (14)57.03 Volatility14.18% 15.44%
Employees21 Debt/Eq0.10 Sales Y/Y TTM-46.29% Profit Margin-1866.29% Recom1.00 Target Price8.00
Option/ShortNo / Yes LT Debt/Eq0.06 EPS Q/Q99.66% Payout- Rel Volume0.14 Prev Close1.19
Sales Surprise- EPS Surprise0.00% Sales Q/Q-61.66% EarningsApr 19 BMO Avg Volume2.91M Price1.25
SMA2015.54% SMA5015.94% SMA200-56.86% Trades Volume105,221 Change4.71%
Date Action Analyst Rating Change Price Target Change
Feb-08-24Initiated Ladenburg Thalmann Buy $8
May-15-24 03:58AM
May-09-24 08:00AM
Apr-30-24 11:52AM
Apr-28-24 12:01PM
Apr-26-24 03:18PM
08:30AM Loading…
Apr-19-24 08:00AM
Mar-28-24 11:22AM
Mar-01-24 08:00AM
Feb-23-24 08:30AM
Feb-08-24 08:30AM
Feb-07-24 08:30AM
Jan-22-24 08:30AM
Dec-29-23 04:05AM
04:00PM Loading…
Dec-21-23 04:00PM
Dec-19-23 08:42AM
Nov-27-23 09:00AM
Oct-03-23 08:30AM
Sep-29-23 04:30PM
Sep-21-23 08:30AM
Jul-28-23 08:00AM
Jul-24-23 07:30AM
Jul-10-23 08:00AM
Jul-06-23 04:30PM
Jun-22-23 04:15PM
Jun-20-23 08:00AM
Jun-15-23 04:05PM
Jun-14-23 08:30AM
04:05PM Loading…
May-26-23 04:05PM
May-24-23 08:40AM
May-22-23 04:15PM
May-18-23 08:30AM
Apr-28-23 04:30PM
Apr-20-23 01:30PM
Apr-11-23 08:15AM
Apr-06-23 06:33AM
Apr-03-23 08:00AM
Mar-30-23 06:20AM
Biodexa Pharmaceuticals Plc is a drug delivery technology company. It is focused on the research and development of medicines for rare cancers, via both in-house programs as well as partnered programs. The firm's proprietary platform drug delivery technologies are Q-Sphera platform is a disruptive polymer microsphere technology, which is used for sustained release at the microscale to prolong and control the release of therapeutics over an extended period of time from weeks to months; Midasolve platform is an innovative nano saccharide technology, which is used to dissolve drugs at the nanoscale so that they can be administered in liquid form directly and locally into tumors; Midacore platform is an edge gold nanoparticle technology, which is used for targeting sites of disease at the nanoscale. The company was founded in 2000 and is headquartered in Cardiff, the United Kingdom.